By efrat|2024-04-14T09:41:37+00:00April 16th, 2024|All|Comments Off on April 17th 2024- Prof. Nigel Russell- Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations
By efrat|2024-04-08T07:25:13+00:00April 9th, 2024|All|Comments Off on April 10th 2024- Dr. Ofir Wolach- Molecular MRD is Strongly Prognostic in Patients with NPM1-Mutated AML Receiving Venetoclax-Based Nonintensive Therapy
By efrat|2024-03-20T09:54:58+00:00March 24th, 2024|All|Comments Off on March 25th 2024- Prof. Olaf Penack- Prophylaxis and Management of Graft-Versus-Host Disease After Stem-Cell Transplantation for Haematological Malignancies: Updated Consensus Recommendations of the European Society for Blood and Marrow Transplantation
By efrat|2024-03-12T14:17:08+00:00March 19th, 2024|All|Comments Off on March 20th 2024- Prof. Michael Schmitt – Efficacy and safety of extended duration letermovir prophylaxis in recipients of hematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial
By efrat|2024-03-10T07:00:13+00:00March 10th, 2024|All|Comments Off on March 11th 2024- Dr. Adi Zoref Lorenz – Malignancy-Associated Hemophagocytic Lymphohistiocytosis in Sweden: Incidence, Clinical Characteristics, and Survival
By efrat|2024-03-04T08:22:05+00:00March 5th, 2024|All|Comments Off on March 6th 2024- Prof. Katy Rezvani – Safety, Efficacy and Determinants of Response of Allogeneic CD19-Specific CAR-NK Cells in CD19+ B Cell Tumors: a Phase 1/2 Trial
By efrat|2024-02-25T08:13:18+00:00February 24th, 2024|All|Comments Off on Feb 26th 2024- Prof. Marion Subklewe- Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
By efrat|2024-02-22T09:21:29+00:00February 21st, 2024|All|Comments Off on Feb 23rd 2024- Guido Ghilardi & Marco Ruella- T-cell Lymphoma and Secondary Primary Malignancy Risk After Commercial CAR T-cell Therapy
By efrat|2024-02-11T09:53:40+00:00February 13th, 2024|All|Comments Off on Feb 14th 2024- Dr. Joshua Fein- Simple Score of Albumin and CRP Predicts High Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy
By efrat|2024-02-04T08:04:14+00:00February 4th, 2024|All|Comments Off on Feb 5th 2024- Prof. Ali Bazarbachi- Sorafenib Plus Intensive Chemotherapy in Newly Diagnosed FLT3-ITD AML: A Randomized, Placebo-Controlled Study by the ALLG
